

TScan Therapeutics announces \$48M in funding

Client News

July 24, 2019

Gunderson Dettmer client TScan Therapeutics, a company dedicated to unleashing the power of the immune system through life-changing T cell therapies, has announced its Series B financing of \$48 million. Novartis Venture Fund, Novartis Institutes for BioMedical Research (NIBR), Bessemer Venture Partners, GV and founding investor Longwood Fund participated in the round.

In the [announcement of the funding](#) TScan CEO David Southwell said, “I am proud that we have assembled an outstanding team of executives along with top-tier investors to drive development of these products internally and to work externally with corporate partners. We are pleased to welcome Novartis Institutes for BioMedical Research to our Series B financing, as they join the strong core of investors from our Series A round of financing.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Stephen Damato and George Pothoulakis.

Related People





Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Related Services

Early-Stage Company

Featured Insights

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act